New innovation within the Betadine Feminine Care range – BETADINE BV Gel

BETADINE™ BV Gel

Break free from bacterial vaginosis (BV)

Bacterial vaginosis (BV) is the most common cause of abnormal vaginal discharge and has been associated with a range of serious health and reproductive consequences.^1A,2A Despite the availability of a number of oral and intravaginal antibiotic treatment options, its management remains challenging.^1B More than 50 % of women experience recurrent episodes with standard antibiotic-based treatments.^1B,2A  A key factor is the failure of antibiotics to fully eliminate vaginal biofilms adhered to cells lining the vagina that contain abundant Gardnerella vaginalis ^1C, also known as bacterial vaginosis.

BV’s recurrent nature can have a substantial impact on women’s emotional, sexual and social lives.^3A  The most distressing symptom of BV is the distinctive, strong, fishy odour that accompanies a thin, grey or white vaginal discharge.^3B,4A Women report feeling embarrassed, ‘dirty’ and concerned that others may detect the malodour.^3C

BETADINE™ BV Gel is a new, non-antibiotic treatment distributed by Mundipharma South Africa, that has the potential to fulfil areas of unmet clinical need in the treatment of BV.^5A,6D  BETADINE™ BV Gel contains astodrimer sodium, a novel dendrimer-based therapy with a physical mechanism of action that disrupts vaginal biofilms and prevents harmful vaginal bacteria from adhering to vaginal lining, reducing their opportunity to grow whilst allowing normal vaginal flora to replenish.^5A,6A,7A+B This helps to normalise the vaginal pH while relieving odour and discharge.^5A

BETADINE™ BV Gel has proven clinical efficacy and safety in 3 large randomised trials in over 500 patients.^6C,7C+D  BETADINE™ BV Gel provides rapid relief from the unpleasant odour in just 24 hours.^6B Because it acts locally and is not absorbed systemically, BETADINE™ BV Gel avoids potential issues associated with conventional antibiotics such as systemic side effects, antibiotic resistance, and overgrowth of Candida is minimal.^6A+E It has a favourable safety profile and is well tolerated.^6C  BETADINE™ BV Gel is applied once-daily for 7 days.^5B It is available over the counter (OTC) from Clicks and other leading pharmacies.

@BetadineSA

Ends.

_________________________________________________________________________________

About Mundipharma South Africa and the BETADINE® brand

Mundipharma (Pty) Ltd is part of the Mundipharma network of independent associated companies covering most of the world’s pharmaceutical markets. Mundipharma is a prime example of an organisation that consistently delivers high-quality products while standing by the values that represent it.

For more information please visit: www.mundipharma.co.za    

BETADINE® is an important and well-established consumer healthcare brand in the Mundipharma portfolio with trusted products used by healthcare professionals and consumers around the world for over 60 years. The launch of the BETADINE™ Daily Intimate Care range represented the brand’s expansion into the Feminine Care category in South Africa. It was voted ‘Product of the Year 2019’ in the South African Consumer Survey of Product Innovation. BETADINE™ BV Gel represents a true innovation in the management of BV and is a welcome addition to the BETADINE® Feminine Care range.

For more information about BETADINE™ BV Gel please visit www.betadine.co.za

BETADINE™ BV Gel. Contains astodrimer sodium 10 mg/g (1 %). BETADINE™ BV Gel also contains purified water, carbomer homopolymer type A, sodium hydroxide, glycerine, propylene glycol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate and edetate disodium dihydrate. Please refer to the instructions for use for full prescribing information. Please report any suspected adverse events to ZAdrugsafety@mundipharma.co.za. Mundipharma (Pty) Ltd, Block D, Grosvenor Square, Park Lane, Century City, Cape Town, South Africa, 7441. www.mundipharma.co.za.

References:

1. Munzy CA, et al. Sex Transm Dis 2020;47(7):441-446.
2. Happel A-U, et al. MedRxiv May 2020; https://doi.org/10.1101/2020.05.04.20090282.
3. Bilardi JE, et al. PLoS ONE 2013;8(9):e74378.
4. StatPearls. Bacterial Vaginosis. Available at: https://www.ncbi.nlm.nih.gov/books/NBK459216/. Accessed 20 November 2020.
5. Betadine BV Gel IFU, April 2020.
6. Chavoustie SE, et al. Eur J Obstet Gynecol Reprod Biol 2020;245:13-18.
7. Data on file. Clinical Evaluation Report, July 2018, Starpharma Pty Ltd.

For additional information and education purpose on Bacterial Vaginosis (BV) please refer to PDFs 1 – 4.